ARTICLE | Finance
Invest, not ingest
Why corporate VCs' parents rarely buy their portfolio companies
April 11, 2016 7:00 AM UTC
There are myriad reasons for pharma and big biotech to make investments in fledgling companies through corporate venture arms, but data suggest M&A is not one of them.
The latest example is Nimbus Therapeutics LLC, which last week sold its Nimbus Apollo Inc. subsidiary to Gilead Sciences Inc. (NASDAQ:GILD) for $400 million up front and up to $800 million in development milestones...